MS drug controversy, adoption outcomes in Sweden, and the multi-factorial reality of Alzheimer’s

The BMJ Podcast by The BMJ

A blockbuster MS drug undergoes FDA re-evaluation. We explore the story of Ocrelizumab, a treatment for primary progressive multiple sclerosis, following a patient petition that highlighted internal disagreements among a...View more